Clinical trial
Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for…
NCT00251498 · Veeda Oncology, Other · Completed
Key facts
| NCT number | NCT00251498 |
|---|---|
| Title | Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer |
| Official title | Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Veeda Oncology, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Cetuximab |
| Enrollment | 82 |
| Completion | Oct 1, 2007 |
| First posted | Nov 10, 2005 |
| Last update posted | Aug 21, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: